Seahorse Executive Jay Teich Receives SFRBM CEO Innovator Award
BILLERICA, Mass., Nov. 20, 2015
Jay Teich, former Seahorse Bioscience CEO, received the first-ever CEO Innovator Award from the Society for Redox Biology and Medicine (SFRBM). This international award recognizes industry leaders who have transformed the face of scientific research in the areas of redox biology and medicine.
Teich received the award in Boston on Nov. 20 during SFRBM 2015, the premier event for cutting-edge research in all aspects of redox biology. Seahorse was acquired by Agilent Technologies on Nov. 1; Teich is now general manager of the Seahorse team at Agilent.
"Led by Jay, Seahorse Bioscience has been an industry leader for many years, developing innovative technologies so many others strive to achieve," said SFRBM president Neil Hogg, Ph.D. "We are thrilled to recognize this achievement and look forward to seeing the next chapter of scientific breakthroughs as Seahorse becomes a part of Agilent."
Seahorse Bioscience XF technology is complementary to Agilent's separations and mass spectrometry solutions, providing a more comprehensive and faster path to researching some of the most challenging diseases affecting humankind. Scientists can now gain a greater understanding of redox biology-the study of electron flow through biological circuits, sensors, and switches-applicable in many areas critical to human health, including cancer, heart disease, aging, cardiovascular disease and obesity.
"I am honored to receive the SFRBM CEO Innovator Award on behalf of my colleagues at Seahorse Bioscience," said Teich. "We remain committed to developing instruments and assay kits for measuring cell metabolism, tools that provide scientists a better understanding of mitochondrial function and disease."
Founded in 1987, the Society for Redox Biology and Medicine is an international organization of 1,200 scientists, investigators and clinicians who conduct research in the area of redox biology. These areas have shown explosive growth over the last decade and are now integral to major initiatives in basic, applied and translational research, including development of new therapies in cancer, heart disease, aging and cardiovascular disease.
About Seahorse Bioscience, a part of Agilent Technologies
Seahorse XF metabolic analyzers and stress test kits make cellular bioenergetic studies simple, efficient and user-friendly. Seahorse customers include scientists at academic institutions, pharmaceutical and biotech organizations. Seahorse is headquartered in Billerica, Massachusetts, U.S., and has regional offices in Copenhagen, Denmark, and Shanghai, China. For more information, visit www.seahorsebio.com.
Agilent Technologies Inc., a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.04 billion in fiscal 2015 and employs about 12,000 people worldwide. Agilent marks its 50th anniversary in analytical instrumentation this year. For more information, visit www.agilent.com.
# # #
+1 408 553 2005